bioAffinity Technologies, Inc. (BIAF)
NASDAQ: BIAF · Real-Time Price · USD
1.180
-0.080 (-6.35%)
Jan 29, 2026, 12:29 PM EST - Market open
bioAffinity Technologies Employees
bioAffinity Technologies had 57 employees as of December 31, 2024. The number of employees decreased by 18 or -24.00% compared to the previous year.
Employees
57
Change (1Y)
-18
Growth (1Y)
-24.00%
Revenue / Employee
$118,890
Profits / Employee
-$258,582
Market Cap
5.30M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 57 | -18 | -24.00% |
| Dec 31, 2023 | 75 | 61 | 435.71% |
| Dec 31, 2022 | 14 | 3 | 27.27% |
| Dec 31, 2021 | 11 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Inotiv | 2,046 |
| FONAR | 535 |
| XWELL | 312 |
| Biodesix | 273 |
| Exagen | 215 |
| Precipio | 60 |
| Advanced Biomed | 31 |
| Mainz Biomed | 26 |
BIAF News
- 22 days ago - bioAffinity Technologies' Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation - Business Wire
- 2 months ago - bioAffinity Technologies' Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable - Business Wire
- 2 months ago - bioAffinity Technologies Reports Third Quarter 2025 Financial Results - Business Wire
- 3 months ago - bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume - Business Wire
- 3 months ago - bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases - Business Wire
- 3 months ago - bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025 - Business Wire
- 3 months ago - bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer - Business Wire
- 3 months ago - bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements - Business Wire